

Wednesday, September 17, 2025 Day 0				
TIME	GALLERY HALL			
9:45 – 10:15	Ribbon Cutting Ceremony of The Exhibition Area			
TIME	Ballroom 1	Ballroom 2	Ballroom 3	
13:00 – 13:30			CENTER STANDARD COMMITTEE Chairman: Sharat Damodar	
13:30 – 14:00		DONOR SAFETY WORKING GROUP Chairman: Yoshihisa Kodera		
14:00 – 14:30	REGISTRY COMMITTEE SESSION Co-chairs: Yoshiko Atsuta, Anthony Dodds, Aloysius Ho			
14:30 – 15:00		Coffee Break		
15:00 – 15:15				
15:15 – 16:00		CORD BLOOD TRANSPLANT WORKING GROUP Chairman: Satoshi Takahashi	NUTRITION MANAGEMENT SUPPORT WORKING GROUP Chairman: Shigeo Fuji	
16:00 – 16:15	EXECUTIVE BOARD MEETING Chairman: Alok Srivastava			
16:15 – 17:00				
18:00 – 21:00	Gala Welcome Riverside Palace			
End of Day 0				

Thursday, September 18, 2025				
Day 1				
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3	VIP 3-4
07:30 – 08:00	Registration			
08:00 – 08:15	Opening Remarks			
08:15 – 10:15	PRESIDENTIAL SYMPOSIUM Defining standards and accreditation of HSCT centers - Impact on quality and access Co-chairs: Alok Srivastava, Corey Cutler, Phu Chi Dung			
	EBMT Perspective (online) Ana Sureda, Barcelona			
	ASTCT Perspective Corey Cutler, Boston			
	LABMT Perspective (online) Cristobal Frutos, Asuncion			
	APBMT Perspective Alok Srivastava, Bengaluru			
10:15 – 10:30	Coffee Break			Nurse Session 1 General HSCT nursing care Co-chairs: Chiang Meng-Kuan (Anne), Vu Thi Bich Huyen
10:30 – 11:15	Plenary Session 1 Evolution of Conditioning Co-chairs: Takanori Teshima, Huynh Van Man Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation (online) John F.DiPersio, St. Louis			Practical experience of NP–nurse collaboration in early intervention for HSCT patients through a Rapid Response System Aoi Kato, Kawasaki
				Program to improve the quality of care and enhance the competency of stem cell transplant nurses at BTH Ngo Thi Xuan Thao, Ho Chi Minh
11:15 – 12:15	MEDAC SPONSORED SYMPOSIUM Treosulfan The Future Standard in Allogenic Stem Cell Transplantation Chairman: Aloysius Ho			
	Reduced-Intensity Treosulfan: Efficacy and Applications Friedrich Stölzel, Kiel			
	High-Intensity Treosulfan: Efficacy and Applications Filippo Milano, Seattle			
12:15 – 13:00	Lunch Break			
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3	VIP 3-4
13:00 – 14:30	Session 1 Donor Selection/ Alternative Donor SCT Co-chairs: Shigeo Fuji, Damai Santosa Allo-SCT in the elderly—Is there an upper limit? Rajneesh Nath, New Brunswick Optimizing Single Cord Blood Transplantation: Insights and Progress from Japan Junya Kanda, Kyoto Approach to Donor Selection in India: Registry Data Navin Khattry, Navi Mumbai	Session 2 Pediatric HSCT (non-malignancy) Co-chairs: Shanika Vitharana, Huynh Nghia Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Hyoung Jin Kang, Seoul HSCT Outcomes in Pediatric Inherited Bone Marrow Failure Syndromes (online) Maryam Behfar, Tehran Primary HLH/PID (online) Mary Slatter, Newcastle upon Tyne	Multidisciplinary Session 1 Laboratory Co-chairs: Chris Hogan, Cao Sy Luan Model-informed precision dosing of intravenous busulfan in Thai pediatric patients Apichaya Puangpetch, Bangkok Assessment of minimal residual disease using next-generation sequencing in acute myeloid leukemia and myelodysplastic syndromes Phan Thi Xinh, Ho Chi Minh The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation (online) Fang Zhou, Jinan	Nurse Session 2 Long-term follow-up care Co-chairs: Ayako Mori, Ma Xuan Tuan
				Vaccination following hematopoietic stem cell transplant Hisayo Doi, Kobe
				Long-Term Care Model for Allo-HSCT Patients via HSCT Platform Chiang Meng-Kuan, Taipei
				Long-Term Follow-Up Care After Hematopoietic Stem Cell Transplantation (online) Min-Ji Kwak, Seoul
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3	VIP 3-4
14:30 – 15:30		MILTENYI SPONSORED SYMPOSIUM Engineering the Future: Graft Optimization and On-Site Manufacturing in Cell and Gene Therapeutics Coordinator: Ranga Prakash		NURSE COMMITTEE MEETING Co-chairs: Miho Suzuki, Chiang Meng-Kuan
		CAR-T Cell therapy for lymphoma and acute leukemia at low cost Nguyen Thanh Liem, Ha Noi		
		Ex vivo T-cell depletion and point-of-care manufacturing of donor lymphocyte infusion and haematopoietic stem cell therapy Pamela Lee, Hong Kong		
		Development of CAR-T for ALL: Investigator-Initiated Trial in Korea Hyoung Jin Kang, Seoul		
15:30 – 15:45	Coffee Break			
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3	VIP 3-4
15:45 – 17:15	Session 3 Long-term follow-up Co-chairs: Jacek Toporski, Keith Fay Multi-centre RCT of a Telehealth intervention program for BM Transplant survivors David Ma, Sydney Survivorship after Allogeneic Stem Cell Transplantation: Quality of Life and Factors Associated with Return to Work (online) Dominique Bron, Lyon International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update (online) Helene Schoemans, KU Leuven	Session 4 CAR-T Cell Therapy Clinical Aspect Co-chairs: Shaomei Feng, Phu Chi Dung Real-world experience of sourcing & establishing CART service in a resource limited centre in our region, The Hong Kong story Joycelyn SIM, Hong Kong International referral and cooperation for difficult HSCT and CAR-T cell therapy: Example in Taiwan Li Chi Cheng, Hualien Aiming for More Appropriate Management of Complications in Chimeric Antigen Receptor (CAR-) T Cell Therapy Naokazu Nakamura, Kyoto	Session 5 HSCT Complication – Infection Co-chairs: Chin Sum Cheong, Hoang Duy Nam Strategies for Preventing and Managing HBV Reactivation after Allogeneic HSCT Masahiro Onozawa, Hokkaido BK polyomavirus infection after hematopoietic cell transplantation Takehiko Mori, Tokyo Granulocytes infusion for severe infection transplant patients at NIHBT Vo Thi Thanh Binh, Ha Noi	Nurse Session 3 CAR-T cell therapy Co-chairs: Miho Suzuki, Huynh Thien Ngon
				Key Nursing Points for CAR-T Cell Therapy Mayumi Sumita, Hokkaido
				Adoptive Cellular Therapy post HSCT (online) Pham Thi Ngoc Anh, Singapore
				CAR-T Cell Therapy Experience in Taiwan (online) Hung, Yen-Ping, Taipei
TIME	BALLROOM HALL			VIP 3-4
17:15 – 18:30	POSTER SESSION			Nurse Oral Presentation Chairman: Manisha Makwana
				Clinical Characteristics And Nursing Care of Elderly Patients With Malignant Hematopathy Treated By Allogeneic Hematopoietic Stem Cell Transplantation Zhang Qiuhui
				Feasibility and safety of continuous nasogastric tube feeding during neutropenic phase for children undergoing hematopoietic stem cell transplantation: role of nurses in nutrition and feeding Deepika Dhamodharan
				Nursing interventions to reduce the impact of skin toxicity following thiotepa/treosulfan-based conditioning in children undergoing hematopoietic stem cell transplantation Mahalakshmi V P
				The role of nurses in recognition and treatment of Cytokine Release Syndrome in haploidentical hematopoietic stem cell transplantation in children Sharmila Devaraj
				Assessment of Quality Of Work Life In Bone Marrow Transplant Nurses Using The Work-Related Quality Of Life (WRQoL) Scale Geena Sunny Mulakkal
				Assessment of Knowledge and Attitude of Nurses on Diet Modification In Gastrointestinal Graft-Versus-Host Disease (GI-GVHD) Gitanjali Sanjay Patil
				Nursing effect of a case of perianal soft tissue infection combined with external application of traditional Chinese medicine in acute myeloid leukemia Zhenghong Hu
End of Day 1				

Friday, September 19, 2025 Day 2				
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3	
07:30 – 08:30	Registration			
08:30 – 10:00	Session 6 CAR-T Cell Therapy Laboratory aspect Co-chairs: Yoshiki Akatsuka, Phan Thi Xinh Development of piggyBac transposon method, a non-viral gene delivery platform, for CAR-T manufacturing for clinical trials Yoshiyuki Takahashi, Nagoya CAR T –Cell therapy in Resource Limited Setting Gaurav Narula, Mumbai Point-of-care manufacturing of CAR-T cell therapy in Vietnam: Opportunity - Challenge – Solution Cao Sy Luan, Ho Chi Minh	Session 7 Pediatric HSCT (malignancy) Co-chairs: Usanarat Anurathapan, Cai Thi Thu Ngan CMV infection in Pediatric Hematopoietic Stem Cell Transplantation in Low & Middle-Income Countries Hany Ariffin, Kuala Lumpur Hematopoietic stem cell transplantation in children with acute leukemia at the Ho Chi Minh City Hematology and Blood Transfusion Hospital, Vietnam Huynh Nghia, Ho Chi Minh A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: the Japan Children’s Cancer Group Neuroblastoma Committee Trial JN-H-11 and JN-H-15 Kimikazu Matsumoto, Tokyo	Multidisciplinary Session 2 Unrelated donor registry HSCT Co-chairs: Tsuneo Takahashi, Tran Trung Dung Japan marrow donor program Takahiro Fukuda, Tokyo Is there a place for unrelated donor in HSCT in 2025? Dominique Masson, Lyon Donor selection in allogeneic transplantation: role of unrelated donor registries Glen Kennedy, Brisbane	
	Coffee Break			
	10:00 – 10:30	Plenary Session 2 Evolution of GVHD prophylaxis Co-chairs: William Hwang, Suradej Hongeng Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide Leo Luznik, Baltimore		
	10:30 – 11:15			
TIME	VIP 3-4		LI BAI	
11:30 – 12:15	MEETING WITH EXPERTS PTCy as uniformed GVHD prophylaxis for all patients undergoing HSCT Leo Luznik, Baltimore Management of Chronic GHVD Corey Cutler, Boston Alternative donor transplantation with a focus on cord blood approaches for patients with high-risk disease Filippo Milano, Seattle HSCT as an Option for Monogenic Immunodysregulatory and Autoinflammatory Disorders Pamela Lee, Hong Kong Choosing the Optimal Conditioning Regimens Friedrich Stölzel, Kiel Management of GVHD and Infection after allogeneic HCT Takahiro Fukuda, Tokyo		GENERAL COUNCIL MEETING Co-chairs: Alok Srivastava	
12:15 – 12:45				
11:30 – 13:00	Lunch Break			
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3	
13:00 – 14:30	ORAL PRESENTATION Chairman: David Kliman Allogeneic Hematopoietic Stem Cell Transplantation as Consolidation Therapy After BCMA CAR-T Cell Treatment Significantly Improves Overall Survival in Patients with Extramedullary Plasmacytoma and Plasma Cell Leukemia Lixia Ma Clinical Outcomes of Locally Manufactured CD19 CAR-T Cell Therapy for Relapsed/Refractory B-ALL and B-NHL in Malaysia S. Fadilah Abdul Wahid IL-17A and IL-18 as Key Predictors in a Novel Model for Severe aGVHD Post-Allogeneic Hematopoietic Stem Cell Transplantation Jiaxin Cao Polatuzumab-based Chemotherapy Followed by CAR-T Therapy in Relapsed/Refractory Burkitt Lymphoma: A Real-World Analysis Rui Liu The Impact of Letermovir Prophylaxis in Matched Sibling Donor Hematopoietic Stem Cell Transplantation: Selecting the Appropriate Population for Optimal Prophylactic Therapy Sisi Zhen Veno-Occlusive Disease in Hematopoietic Stem-Cell-transplant: A Multi-Year Review of Patterns, Treatment Challenges, and Outcomes Saswata Saha Busulfan Versus Fludarabine Conditioning Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Fanconi Anemia Maryam Behfar Fifteen year follow up of haploidentical HSCT for children with IEI - TCR-αβ/CD 19 depleted or T replete graft with post-transplant cyclophosphamide in children undergoing haploidentical hematopoietic stem cell transplant for inborn error of immunity Kavitha Ganesan	ORAL PRESENTATION Chairman: Li Chi Cheng Reduced- Versus Standard-Dose Melphalan as Single-Agent Conditioning Regimen in Autologous HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis Rowel David D. Yap Incidence and Risk Factors for Zoster Reactivation Post Haematopoietic Stem Cell Transplant in Singapore General Hospital Aw Jialing Minute FLT3-ITD Clones Detected at Day +30 After Allo-HSCT Identify High Risk of Relapse and Guide Subsequent Maintenance Therapy in AML Patients: A NICHE Cohort Study Shan Jiang Virtual Screening of Phytochemical Library of Indian Medicinal Plants for Transplant Associated Thrombotic Microangiopathy Vikram Gota Early Immunological Predictors of Cytomegalovirus (CMV) Infection After Allogeneic Hematopoietic Stem Cell Transplantation in a High Seropositive Population Shahnaz Sharifah binti Syed Abd Kadir Efficacy and Safety of Romiplostim in Treating Thrombocytopenia After Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial Zahra Karimizadeh Haploidentical HSCT in Pediatric Leukemias: TCR Alpha/Beta Depleted Transplant vs. Post-Transplant Cyclophosphamide- A Single Center experience Sunil Bhat Clinical Impact of Donor-Source on Allogeneic Hematopoietic Cell Transplantation for Childhood ALL: A Report from JSTCT Pediatric ALL-WG Hirotoishi Sakaguchi	Multidisciplinary Session 3 Quality Management/FACT-JACIE/Analyzing and reporting outcomes Co-chairs: Minako Iida, Aloysius Ho Quality management: FACT-JACIE Standards Mickey Koh, Singapore Data Management of HCT Experience and Reflections Jia Chen, Suzhou Advancing HCT Research: Strategies for Analyzing Outcomes and Promoting Registry Studies Yoshiko Atsuta, Nagakute	
	Coffee Break			
	15:00 – 16:30	Session 8 Conditioning Regimen Co-chairs: Wasanthi Wickramasinghe, Nguyen Hanh Thu Treosulfan-based conditioning for allogeneic HSCT in children with non-malignant diseases Ho Joon Im, Seoul Safety and efficacy of VA combined with modified BuCy conditioning regimen followed by allo-HSCT for high-risk or refractory/relapsed acute lymphoblastic leukemia: a prospective, single-center, single-arm clinical trial Xiaowen Tang, Suzhou Radiation-free alternative donor transplant in PID (online) Dimana Dimitrova, Bethesda	Session 9 Haplo-HSCT Co-chairs: Sharat Damodar, Phu Chi Dung Double Down: The U.S. Haplo-Cord Experience in Allogeneic Transplantation Filippo Milano, Seattle Haploidentical - HSCT for malignant hematology diseases: Experience at BTH Huynh Van Man, Ho Chi Minh Less is More: The Evolution of PTCy Dose for Safer Allogeneic Transplantation (online) Junichi Sugita, Sapporo	Session 10 Complication – GVHD Co-chairs: Gin Gin Gan, Clinton Lewis Low dose PT-Cy as GVHD prophylaxis Mikhail Drovkov, Moscow/Tashkent Recent Advances in GvHD Research: From Bench to Bed (online) Yang Xu, Suzhou GVHD Update EBMT Guidelines (online) Olaf Penack, Berlin
	TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3
	16:30 – 17:30	POSTER SESSION		
End of Day 2				

Saturday, September 20, 2025 Day 3			
TIME	BALLROOM 1	BALLROOM 2	BALLROOM 3
07:30 – 08:30	Registration		
08:30 – 10:00	Session 11 Lymphoma/Myeloma Co-chairs: Lallindra Gooneratne, Trinh Thuy Duong Autologous stem cell transplantation from 2011 to 2022 in Japanese patients aged ≥ 65 years with relapsed or refractory diffuse large B-cell lymphoma Satoshi Yamasaki, Fukuoka Advances in the management of multiple myeloma Adam Bryant, Sydney Revisiting the standard 200 mg/m² dose of melphalan for autologous transplant in myeloma in the era of MRD Sumeet Mirgh, Mumbai	Session 12 Enhancing Access to HSCT: Establishing services with limited resources Co-chairs: Alok Srivastava, Huynh Van Man Experience in establishing services with limited resources Venkatesh Ekbote, Aurangabad Abhijeet Ganapule, Kolhapur R. M. Subbaiah, Tiruchirappalli Shailesh Lavana, Gujarat	Session 13 Leukemia, MDS, MPN Co-chairs: Than Hein, Ngo Ngoc Ngan Linh Allogeneic HSCT in relapsed AML Friedrich Stölzel, Kiel FORUM study: HSCT in children and adolescents with acute lymphoblastic leukemia Yves Bertrand, Lyon Maintenance therapy after allo-HSCT for AML/MDS Phu Chi Dung, Ho Chi Minh
	Coffee Break		
10:30 – 11:15	Plenary Session 3 Artificial Intelligence in HSCT Co-chairs: Bor-Sheng Ko, Vo Thi Thanh Truc Hematopoietic Stem Cell Transplantation: Risk Stratification, Machine Learning, and Models Jing Liu, Peking		
11:15 – 12:00	AWARD ANNOUNCEMENTS AND CLOSING REMARKS		
End of Day 3			